Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Pfizer Inc. NYSE: PFE. In a filing disclosed on May 31st, the Representative disclosed that they had bought between $15,001 and $50,000 in Pfizer stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
- Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
- Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
- Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
- Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
- Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
- Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
- Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
- Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
- Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.
Pfizer Stock Performance
Pfizer stock traded up $0.07 during mid-day trading on Wednesday, reaching $23.42. The company's stock had a trading volume of 24,477,042 shares, compared to its average volume of 40,980,394. The firm's fifty day moving average price is $23.05 and its two-hundred day moving average price is $25.03. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a market capitalization of $133.15 billion, a P/E ratio of 16.61, a PEG ratio of 0.64 and a beta of 0.58.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period last year, the company earned $0.82 earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.34%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is currently 124.64%.
Wall Street Analyst Weigh In
PFE has been the topic of several research analyst reports. UBS Group upped their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $29.17.
Check Out Our Latest Analysis on Pfizer
Hedge Funds Weigh In On Pfizer
A number of large investors have recently bought and sold shares of the stock. Norges Bank purchased a new stake in Pfizer during the 4th quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Pacer Advisors Inc. lifted its holdings in Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after buying an additional 17,957,928 shares during the period. Amundi grew its position in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after buying an additional 15,758,846 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Pfizer during the first quarter valued at approximately $389,861,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
